title: Atorvastatin effect on the distribution of high-density lipoprotein subfractions and human paraoxonase activity.
abstract: Human serum paraoxonase-1 (PON1) protects lipoproteins against oxidation by hydrolyzing lipid peroxides in oxidized low-density lipoprotein (LDL); therefore, it may protect against atherosclerosis. Changes in the ratio of high-density lipoprotein (HDL) subfractions may alter the stability and the antioxidant capacity of PON1. The aim of the study was to examine the effect of atorvastatin treatment on the distribution of HDL subfractions, LDL size, cholesteryl ester transfer protein (CETP), lecithin-cholesterol acyltransferase (LCAT), and PON1 activity. In all, 33 patients with type IIa and IIb hypercholesterolemia were involved in the study. LDL sizes and HDL subfractions were determined by gradient gel electrophoresis. CETP, LCAT, and PON1 activities were measured spectrophotometrically. Three months of treatment with atorvastatin 20 mg daily significantly increased the HDL3 (+8.13%) and decreased the HDL2a and HDL2b subfractions (-1.57% and -6.55%, respectively). The mean LDL size was significantly increased (+3.29%). The level of oxidized LDL was significantly decreased (-46.0%). The PON1 activity was augmented by the atorvastatin treatment (+5.0%). The CETP activity positively correlated with the HDL2b level and negatively correlated with the HDL3 and HDL2a levels. Atorvastatin alters the HDL subfractions, which may improve its antiatherogenic effect via enhancement of the PON1 activity.
authors.affiliation: First Department of Medicine, University of Debrecen Medical and Health Science Center, Debrecen, Hungary. mharangi@hotmail.com
authors.forename: Mariann
authors.initials: M
authors.lastname: Harangi
authors.forename: Hossein Z
authors.initials: HZ
authors.lastname: Mirdamadi
authors.forename: Ildikó
authors.initials: I
authors.lastname: Seres
authors.forename: Ferenc
authors.initials: F
authors.lastname: Sztanek
authors.forename: Miklós
authors.initials: M
authors.lastname: Molnár
authors.forename: Andrea
authors.initials: A
authors.lastname: Kassai
authors.forename: Zoltán
authors.initials: Z
authors.lastname: Derdák
authors.forename: László
authors.initials: L
authors.lastname: Illyés
authors.forename: György
authors.initials: G
authors.lastname: Paragh
mesh_terms: D000328:Adult; D000368:Aged; D043303:Aryldialkylphosphatase / Q000097:blood*; D000069059:Atorvastatin; D053480:Cholesterol Ester Transfer Proteins / Q000097:blood; D006538:Heptanoic Acids / Q000494:pharmacology*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology*; D008075:Lipoproteins, HDL / Q000097:blood*; D008875:Middle Aged; D007862:Phosphatidylcholine-Sterol O-Acyltransferase / Q000097:blood; D011758:Pyrroles / Q000494:pharmacology*
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D006538:Heptanoic Acids; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D008075:Lipoproteins, HDL; D011758:Pyrroles; D000069059:Atorvastatin; D007862:Phosphatidylcholine-Sterol O-Acyltransferase; D043303:Aryldialkylphosphatase